Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis
Articles > Article · 2007
Authors: Murat AKYILDIZ, Abdullah Zeki KARASU, Murat ZEYTÜNLÜ, Unal AYDIN, Tijen OZACAR, Murat KILIÇ
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Journal Indexed in SCI Expanded, International, 2007, vol 22, pp 2130-2134
DOI: 10.1111/j.1440-1746.2006.04609.x
Summary
Background and Aim: Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy. Because HBV reinfection has a severe course and could result in graft failure in liver transplant recipients, prompt medication is essential. Herein is reported the authors' experience with adefovir dipivoxil (AD) therapy in 11 liver transplant recipients who had HBV reinfection despite the administration of lamivudine and HBIG.